ImmunoGen’s Mirvetuximab Confidence Justified With Ovarian Cancer Win

Success Follows Accelerated Approval Setback In 2019

 
• By Mandy Jackson

The response rate, with five complete responses, exceeds known responses to standard-of-care chemotherapy in heavily pre-treated folate receptor alpha-high patients. A US FDA filing is on track for early 2022.

Happy Woman traveler over mountains raised hands
Phase III success was achieved in folate receptor alpha-high ovarian cancer • Source: Alamy

More from Clinical Trials

More from R&D